NASDAQ: ACIU - AC Immune SA

Rentabilité sur six mois: +32.23%
Secteur: Healthcare

Calendrier des promotions AC Immune SA

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Plus de détails
The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Выручка 0.111
EBITDA 0.0465
P/S 5.38
P/BV 2.19
EV/EBITDA 8.74
P/E 13.14
Цена ао 3.39
ISIN CH0329023102
Число акций ао 0.08469 млрд
Сайт https://www.acimmune.com
Валюта usd
IPO date 2016-09-23
Sector Health Care
Industry Biotechnology
Валюта отчета chf
Changement de prix par jour: +0.3135% (3.19)
Changement de prix par semaine: -5.6% (3.39)
Changement de prix par mois: -7.51% (3.46)
Changement de prix sur 3 mois: -8.05% (3.48)
Changement de prix sur six mois: +32.23% (2.42)
Changement de prix par an: +15.52% (2.77)
Evolution du prix sur 3 ans: -50.69% (6.49)
Evolution du prix sur 5 ans: -36.63% (5.05)
Evolution des prix depuis le début de l'année: +5.61% (3.03)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 21.21 1
P/BV 1.95 7
P/E 0 0
EV/EBITDA -4.75 0
Total: 4.38

Efficacité

Nom Signification Grade
ROA, % -29.67 0
ROE, % -33.76 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0694 10
Total: 9.6

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -86.67 0
Rentabilité Ebitda, % -208.31 0
Rentabilité EPS, % -192.8 0
Total: 0
Plus de détails

Établissements Volume Partager, %
BVF Inc. 7428379 8.8
Avidity Partners Management, LP 2969800 3.52
Morgan Stanley 1741677 2.06
Platinum Investment Management Ltd 1322462 1.57
Wells Fargo & Company 1146086 1.36
Renaissance Technologies, LLC 425179 0.5
Deutsche Bank Aktiengesellschaft 253375 0.3
Eversept Partners, LP 124589 0.15
Assenagon Asset Management S.A. 111418 0.13
Handelsbanken Fonder AB 101064 0.12

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
ProShares Ultra Nasdaq Biotechnology 0.0238 51.697637072723 0.85651
Invesco Nasdaq Biotechnology ETF 0.03512 28.578975171685 0.8565
Principal Healthcare Innovators ETF 0.03418 618.4964157054 0.8416
Future Tech ETF 0.03418 426.33969118983 0.8416



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Andrea Pfeifer Ph.D. Co-Founder, CEO & Director 1.1M 1957 (67 années)
Mr. Christopher Roberts CFO & VP of Finance N/A 1990 (34 année)
Mr. Piergiorgio Donati Chief Technical Operations Officer N/A 1971 (53 année)
Mr. Jean-Fabien Monin Chief Administrative Officer N/A 1971 (53 année)
Mr. Howard Donovan Chief HR Officer N/A 1976 (48 années)
Mr. Alexandre Caratsch General Counsel N/A 1966 (58 années)
Mr. Julian Snow VP of U.S. Finance & Corporate Development N/A
Ms. Madiha Derouazi Chief Scientific Officer N/A 1973 (51 année)
Dr. Gary Anthony Waanders Ph.D. Senior VP of Investor Relations & Corporate Communications N/A 1964 (60 années)
Dr. David T. Hickman Head of AD - SME

Adresse: Switzerland, Lausanne, Building B - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.acimmune.com